GT Molecular Wins CDC's National Wastewater Surveillance System Multi-Pathogen Assay Development Contract

News provided by

Sep 12, 2024, 14:25 ET

FORT COLLINS, Colo., Sept. 12, 2024 /PRNewswire/ -- GT Molecular, Inc., a company providing ultrasensitive PCR assays for wastewater-based epidemiology, cancer research, and pathogen detection, was awarded the Center for Disease Control's (CDC) National Wastewater Surveillance System (NWSS), Multi-Pathogen Assay Development Optimization, Validation, and Support contract. This work will build upon previously successful contracts with the CDC and incorporate emerging public health threat targets from viral, bacterial, parasitic, fungal, antimicrobial resistance (AMR), infectious disease source tracking, and disease vector categories. The project will span up to five years and emphasizes the continued support for wastewater testing as a part of the nation's public health response. GT Molecular is proud to receive this award and is excited to continue providing the best assays for the nation's wastewater testing needs.

Key takeaways:

The CDC is supporting wastewater testing for public health threats in the years to come
GT Molecular has and continues to be at the forefront of wastewater-based epidemiology pathogen testing
More targets and multiplexed PCR assay kits are in development for a variety of digital and RT-PCR platforms from QIAGEN®, Bio-Rad®, and Roche®!

GT Molecular is empowering hundreds of academic, commercial, and public testing laboratories around the world with its easy-to-use and accurate PCR assay kits as well as its national testing and sequencing services.

Contact us!
Please reach out to us to learn more or to be added to our update list for new and upcoming CDC assay kit releases! www.gtmolecular.com and [email protected]

Disclaimer: Reference to specific commercial products, manufacturers, companies, or trademarks does not constitute its endorsement or recommendation by the U.S. Government, Department of Health and Human Services, or Centers for Disease Control and Prevention.

About GT Molecular
With its GT-Plex™ patented and patent-pending technology, GT Molecular is a leader in providing ultrasensitive, multiplexed digital PCR and qPCR tests. GTM's technology for highly multiplexed assays provide a user friendly, out-of-box solution for rapid deployment with reliable and consistent measurements while detecting as little as 3-4 molecules of target nucleic acid. In addition to its presence in wastewater-based epidemiology, the company has a growing catalog that includes multiplexed PCR Kits for oncology genes and pathogen detection – including respiratory panels, SARS-CoV-2 + Variants, gastrointestinal/enteric, AMR, and others. For more information, please visit us at www.gtmolecular.com and follow us on LinkedIn and X.

https://www.linkedin.com/company/gt-molecular/
https://twitter.com/GTMolecular

SOURCE GT Molecular